DiaMedica Therapeutics Inc. has announced its financial results for the third quarter of 2026, revealing significant progress in its clinical trials. The company, which focuses on developing innovative treatments for serious medical conditions, has completed enrollment in key studies and is preparing for important upcoming presentations.
On November 12, 2026, DiaMedica disclosed its condensed consolidated financial results for the quarter ended September 30, 2026. This update is crucial as it reflects the company's ongoing commitment to advancing its clinical programs, particularly in areas such as fetal growth restriction and acute ischemic stroke.
Background
DiaMedica Therapeutics Inc. operates within the pharmaceutical preparations sector, specifically focusing on developing novel treatments for conditions like preeclampsia, fetal growth restriction, and acute ischemic stroke. The company is listed on the Nasdaq under the ticker DMAC and is categorized as a smaller reporting company.
What the Filing Says
The filing indicates that DiaMedica has made significant strides in its clinical trials. The company completed enrollment in the first two cohorts of its Phase 2 early-onset fetal growth restriction trial. Additionally, it surpassed the 200-participant enrollment threshold for the ReMEDy2 Phase 2/3 acute ischemic stroke trial. A conference call is scheduled for November 13, 2026, to discuss these developments further.
Impact
This progress may affect various stakeholders, including investors, healthcare professionals, and patients. The advancements in clinical trials could lead to new treatment options for serious conditions, enhancing the company's reputation and competitive edge within the pharmaceutical industry.
What's Next
DiaMedica has scheduled a key opinion leader event on November 24, 2026, where preliminary results from the first two cohorts of the fetal growth restriction study will be presented. This event is expected to provide further insights into the company's clinical advancements.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










